Avallano Strengthens Leadership with New Chief Strategy Officer to Drive AI-Powered Clinical Research Innovation
26 Junio 2024 - 2:00AM
Business Wire
Avallano, an AI-enabled clinical research company, today
announced the appointment of Michael A. Ibara, Pharm.D., as Chief
Strategy Officer (CSO). Dr. Ibara will lead the company’s global
strategic initiatives to transform the clinical trial sector with
leading-edge technology solutions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240625120270/en/
Michael A. Ibara, Pharm.D., Chief
Strategy Officer (CSO). (Photo: Business Wire)
Dr. Ibara will lead the launch of Avallano’s generative AI
technologies, aimed at enhancing clinical research by addressing
the challenges faced by patients, sites, and sponsors in executing
clinical trials. Avallano’s solutions include personalized patient
chat services, AI-driven medical information processing, founded on
a market-leading approach to global privacy and patient
empowerment. He’ll guide the company in balancing regulatory
compliance requirements with the capabilities of explainable
AI.
“Michael’s extensive experience in the biopharmaceutical
industry and his innovative approach to data and clinical
operations make him the perfect fit for Avallano,” said Paul Della
Maggiora, Co-Founder and CEO. “We have already benefited from
Michael’s strategic vision as an advisor and are confident that his
leadership will help us achieve our ambitious goals and continue to
provide exceptional service to our clients.”
Prior to joining Avallano, Dr. Ibara served as Chief Data
Officer at Elligo Health Solutions, where he created an innovative
approach to utilize electronic health record (EHR) data for
clinical trial feasibilities and operations. In addition to
developing the first-ever effort to automate the collection of
adverse events directly from EHRs, he has held senior leadership
positions in large biopharmaceutical and CRO organizations. Dr.
Ibara holds a Pharm.D. from the University of Michigan and a
Fellowship from the University of North Carolina and Burroughs
Wellcome Co.
“I am delighted to join Avallano at such an exciting time in the
company’s growth,” said Dr. Ibara. “I look forward to working with
the team to develop AI-driven solutions to improve clinical
research and deliver innovative solutions to help patients get
better value from participating in clinical trials.”
About Avallano
Imagine a world where your life sciences data aren’t just
numbers and figures but a powerful tool to drive engagement and
education. We transform your data into actionable insights and
harness its potential to create impactful patient and community
engagement apps. We’re not just about data; we’re about making
research benefits tangible and understandable to patients and
communities. Turn your data into action and unlock the true
potential of your research network.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625120270/en/
Michael Ibara michael@avallano.com